Clinical trials: BCG Infection
BCG Vaccination Reaction, Tuberculosis
A Study of GC3107(BCG Vaccine) in Healthy Infants
The purpose of this study is to investigate the efficacy and safety of GC3107 in healthy infants
- Trial name
- NCT03947138
- Testing
- GC3107, Intradermal BCG SSI inj.
- Where
- 2 sites in South Korea
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Tuberculosis
Randomized Controlled Trial of Percutaneous and Intradermal BCG Vaccination.
An open label, randomized, controlled, equivalency trial to compare the efficacy of the percutaneous route of administration with the intradermal route of administration of Japanese (Tokyo) 172 BCG, in the prevention of…
- Trial name
- NCT00242047
- Testing
- Japanese (Tokyo) 172 Bacille Calmette Guerin (BCG).
- Where
- South Africa
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
Tuberculosis
Should Low Birth Weight Infants Be Vaccinated With BCG Vaccine at Birth in Developing Countries?
The World Health Organization (WHO) currently recommends BCG vaccination at birth in developing countries. Pre-term infants should be vaccinated when they reach the chronological age of 40 weeks.
- Trial name
- NCT00146302
- Testing
- Bacille Calmette Guerin (BCG)
- Where
- Guinea-Bissau
- Volunteers
- 2,320 people
- Sponsor
- Bandim Health Project
Allergy, Eczema
Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction
1. To determine if BCG immunisation at birth, compared to no BCG immunisation, leads to a reduction in measures of allergy and infection in the first 12 months of life. 2.
- Conditions
- Allergy, Eczema, Respiratory Tract Infections
- Trial name
- MIS BAIR (NCT01906853)
- Testing
- BCG
- Where
- 2 sites in Australia
- Volunteers
- 1,272 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Tuberculosis
Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients
A total of 60 TB patients aged 65 years and below who are randomly assigned to the experimental group and the control group. The experimental group is injected with BCG-PPD test drug once, and the control group is injected with…
- Trial name
- NCT04538911
- Testing
- BCG-PPD
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Severe Illness, Septicaemia
Early Versus Late BCG Vaccination in HIV-1 Exposed Infants in Uganda in Uganda
BCG vaccination may have non-specific effects (NSE) i.e., additional benefits on childhood morbidity and mortality that are separate the vaccine's effect on the incidence of disseminated tuberculosis.
- Conditions
- Severe Illness, Septicaemia, Diarrhoea, Lower Respiratory Infection
- Trial name
- NCT02606526
- Testing
- BCG at birth, Control arm: Delayed BCG
- Where
- Uganda
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Makerere University
HIV Exposure, HIV Infection
Early Versus Delayed BCG Vaccination of HIV-exposed Infants
In sub-Saharan Africa (SSA), more than 300,000 babies with HIV die each year. HIV-infected children develop AIDS and die faster in SSA than those in developed countries.
- Trial name
- NCT02062580
- Testing
- BCG
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- University of Cape Town